[First experience in the use of a new Russian narcotic analgesic prosidol in oncology]. / Pervyi opyt primeneniia novogo otechestvennogo narkoticheskogo analgetika prosidola v onkologii.

Prosidol, a new Russian narcotic analgesic, was used in various dosage forms (buccal and oral tablets, injection solution) in 113 cancer patients for the treatment of chronic pain, as a component of total anesthesia, and for postoperative analgesia. The best results were attained with the universal noninvasive dosage form, buccal tablets, used for the treatment of chronic pain in incurable patients. Analgesic properties of buccal prosidol are close to those of tramadol, the drug is well tolerated by the patients and causes no grave side effects. As a drug for postoperative analgesia prosidol was highly effective in patients after extracavitary oncologic surgery and less effective after thoracal and abdominal interventions. As a component of total anesthesia prosidol is inferior to fentanyl and approximately similar to promedol. An advantage of prosidol is its highly effective universal noninvasive dosage form, buccal tablets, which may be used for rapid analgesia in any situation.

[General anesthesia in patients with spontaneous respiration]. / Aktual'nye aspekty obshchei anestezii so spontannym dykhaniem bol'nykh.

Experimental studies performed on 97 alert rats and clinical studies in 930 cancer patients after extracavity surgery have demonstrated the advantage of the elaborated technique of total intravenous anesthesia of patients on spontaneous respiration with microdoses of diazepam, fentanyl, calypsol and droperidol over the current variants of inhalation and intravenous anesthesia with preserved spontaneous respiration. The technique elaborated is characterized by technical simplicity, efficacy, prompt postanesthetic rehabilitation of patients, safety for the personnel and economic benefits. The technique might be useful in mass injuries due to its minimum effect on the basic body functions and possibility of air breathing, with no special devices required.

[The new Soviet narcotic analgesic phenaridine as a component of general anesthesia during cancer surgery]. / Novyi otechestvennyi narkoticheskii analgetik fenaridina kak komponent obshchei anestezii v onkokhirurgii.

The results of studies on 65 cancer patients operated on under modified neuroleptanalgesia using fenaridine give evidence of a more potent and prolonged analgetic effect of a new Soviet narcotic analgesic fenaridine as compared to fentanyl. Fenaridine ensures stable neuroautonomous protection of the body during cancer surgery and is indicated in prolonged traumatic surgical interventions with cardiopulmonary bypass. Along with the above advantages fenaridine possesses all the complex of side effects typical of opiates associated with the depression of respiratory centres, psychoemotional sphere, activation of parasympathetic centres which may complicate the period following the patient's withdrawal from anesthesia and necessitate prolonged controlled lung ventilation in the early postoperative period. Thus, during 3-5-hour-long surgery it is advisable to administer the basic amount of the overall drug dose during the first 1-1.5 h of anesthesia and surgery, which promotes the awakening of most patients 10-15 min after surgery. Another drawback of fenaridine is the onset of marked rigor and signs of microcirculation disturbances upon discontinuation of the drug effect.

[Klofelin as a component of general anesthesia and a means of postoperative analgesia in cancer surgery]. / Klofelin kak komponent obshchei anestezii i sredstvo posleoperatsionnogo obezbolivaniia v onkokhirurgii.

Clophelinum (0.0014 +/- 0.00007 mg/kg, intravenously) as a component of multicomponent general anesthesia eliminated hemodynamic and endocrine reactions during major abdominal and thoracic surgery in cancer patients, reducing the dosage of calypsol and fentanyl. In the postoperative period clophelinum in combination with Baralgin ensures effective analgesia without the use of any narcotic analgesics.

[Clinical aspects of the radioimmunoassay of carcinoembryonic antigen levels in breast cancer]. / Nekotorye klinicheskie aspekty radioimmunologicheskogo issledovaniia urovnia rakovoémbrional'nogo antigena u bol'nykh rakom molochnoi zhelezy.

The paper is concerned with the results of radioimmunoassay of the CEA level in the blood serum of 235 patients with breast cancer, 48 patients with fibrous-cystic mastopathies and 51 healthy women. In 100 patients with generalized breast cancer repeated examination of the CEA level was done during drug treatment. The authors showed a possibility to use in practice the results of radioimmunoassay of CEA in patients with breast cancer in early stages as a prognostic test as well as an additional criterion in the evaluation of drug therapeutic efficacy in patients with generalized breast cancer.